文献

J-GLOBAL ID：201202241524783384   整理番号：12A0376424

トリプルネガティブ表現型は、dose-dense連続補助化学療法で治療した患者の有害予後値のものである:ギリシャ共同腫瘍学グループ(HeCOG)の無作為化第III相試験のコンテキストにおけるトランスレーショナルリサーチの分析

Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial

著者 (26件)： SKARLOS P. (Agios Savvas Cancer Hospital, Dep. of Radiotherapy, Athens, GRC) ,  CHRISTODOULOU C. (Metropolitan Hospital, Second Dep. of Medical Oncology, Piraeus, GRC) ,  KALOGERAS K. T. (Data Office, Translational Res. Section, Hellenic Cooperative Oncology Group, Athens, GRC) ,  KALOGERAS K. T. (Aristotle Univ. of Thessaloniki School of Medicine, Dep. of Medical Oncology, Papageorgiou Hospital, Thessaloniki, GRC) ,  ELEFTHERAKI A. G. (Data Office, Section of Biostatistics, Hellenic Cooperative Oncology Group, Athens, GRC) ,  BOBOS M. (Aristotle Univ. of Thessaloniki School of Medicine, Lab. of Molecular Oncology, Hellenic Foundation for Cancer Res. ...) ,  BATISTATOU A. (Ioannina Univ. Hospital, Dep. of Pathology, Ioannina, GRC) ,  VALAVANIS C. (Metaxas Cancer Hospital, Dep. of Pathology, Piraeus, GRC) ,  TZAIDA O. (Metaxas Cancer Hospital, Dep. of Pathology, Piraeus, GRC) ,  TIMOTHEADOU E. (Aristotle Univ. of Thessaloniki School of Medicine, Dep. of Medical Oncology, Papageorgiou Hospital, Thessaloniki, GRC) ,  KRONENWETT R. (Siemens Healthcare Diagnostics, Cologne, DEU) ,  KRONENWETT R. (Sividon Diagnostics GmbH, Nattermann Allee 1, 50829, Cologne, DEU) ,  WIRTZ R. M. (Siemens Healthcare Diagnostics, Cologne, DEU) ,  WIRTZ R. M. (Stratifyer Molecular Pathology GmbH, Werthmannstrasse 1, 50935, Cologne, DEU) ,  KOSTOPOULOS I. (Aristotle Univ. of Thessaloniki School of Medicine, Dep. of Pathology, Thessaloniki, GRC) ,  TELEVANTOU D. (Aristotle Univ. of Thessaloniki School of Medicine, Lab. of Molecular Oncology, Hellenic Foundation for Cancer Res. ...) ,  KOUTSELINI E. (Metropolitan Hospital, Dep. of Pathology, Piraeus, GRC) ,  PAPASPIROU I. (Alexandra Hospital, Dep. of Pathology, Athens, GRC) ,  PAPADIMITRIOU C. A. (Univ. of Athens School of Medicine, Dep. of Clinical Therapeutics, Alexandra Hospital, Athens, GRC) ,  PECTASIDES D. (Hippokration Hospital, Second Dep. of Internal Medicine, Oncology Section, Athens, GRC) ,  GOGAS H. (Univ. of Athens Medical School, First Dep. of Medicine, Laiko General Hospital, Athens, GRC) ,  ARAVANTINOS G. (Agii Anargiri Cancer Hospital, Third Dep. of Medical Oncology, Athens, GRC) ,  PAVLIDIS N. (Ioannina Univ. Hospital, Dep. of Medical Oncology, Ioannina, GRC) ,  ARAPANTONI P. (Metaxas Cancer Hospital, Dep. of Pathology, Piraeus, GRC) ,  SKARLOS D. V. (Metropolitan Hospital, Second Dep. of Medical Oncology, Piraeus, GRC) ,  FOUNTZILAS G. (Aristotle Univ. of Thessaloniki School of Medicine, Dep. of Medical Oncology, Papageorgiou Hospital, Thessaloniki, GRC)
資料名： Cancer Chemotherapy and Pharmacology  (Cancer Chemotherapy and Pharmacology)
巻： 69  号： 2  ページ： 533-546  発行年： 2012年02月 
JST資料番号： D0065D  ISSN： 0344-5704  CODEN： CCPHDZ  資料種別： 逐次刊行物 (A)
発行国： ドイツ (DEU)  言語： 英語 (EN)

タイトルに関連する用語 (13件)： 表現型 ,  補助化学療法 ,  治療 ,  患者 ,  予後値 ,  ギリシャ ,  共同 ,  腫瘍学 ,  グループ ,  第III相試験 ,  コンテキスト ,  トランスレーショナルリサーチ ,  分析